CEI Weekly: Is There a Future for Generic Biotech Crops?

Friday, September 28, 2012

 

 

Feature: A new CEI study looks at the effect of regulatory policy on crop biotechnology.

FEATURE: Is There a Future For Generic Biotech Crops?

 

Usually when patents expire, new generic markets are allowed to develop. But in the case of crop biotechnology, current U.S. regulatory policy could prevent a market of affordable generic biotech seeds. CEI Senior Fellow Greg Conko explains the situation and proposes regulatory reforms in a new CEI Issue Analysis: "Is There a a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry."

 

 

SHAPING THE DEBATE

 

The Federal Department of Higher Spending and Higher Local Taxes

David Bier's op-ed in The Washington Examiner

 

What Do The War on Cancer and Climate Modeling Have in Common?

Bill Frezza's op-ed in Forbes

 

Field of Cash: If You Offer, They Will Take

Trey Kovacs' op-ed in The Daily Caller

 

Chicago Strike Shows Unions Corrupt Teachers, Harm Students 

Matt Patterson's op-ed in The Washington Examiner 

 

Unions Stack the Deck Against Job Creation

Matt Patterson & Crissy Brown's op-ed in The Washington Times

 

Market Demand Knocks Down Regulatory Barriers in Kansas City Fiber Deployment

Fred Campbell's op-ed in Ars Technica

 

'Bipartisan' Board Donates to Dems Overwhelmingly

John Berlau's citation in The Washington Free Beacon

 

Privacy Bill Requires Search Warrants for Email, Cell Phone Tracking

Ryan Radia's citation in CNET

 

PBS Newshour Omits Obama's Support for Blasphemy Law

Hans Bader's citation on HotAir

 

 

 

 

 

 

 

 

 

 

                     

 

 

CEI PODCAST

 

September 27, 2012: The Future of Generic Biotech Crops

 

Senior Fellow Greg Conko discusses his newpaper, “Is There a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry.” Patents will soon expire for several popular biotech crops, opening the way for cheaper generic versions. But because, unlike prescription drugs, biotech crops have to be re-approved every few years, the future of generic biotech crops is very much in doubt. Conko recommends getting rid of re-approval requirements to put them on the same footing as other products.